Tenaya Therapeutics (TNYA) News Today $1.13 +0.01 (+0.89%) Closing price 04:00 PM EasternExtended Trading$1.12 0.00 (-0.44%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Brokerages Set Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Price Target at $17.33February 10, 2025 | americanbankingnews.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Consensus Recommendation of "Buy" from AnalystsTenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) has been assigned an average recommendation of "Buy" from the six analysts that are currently covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month prFebruary 7, 2025 | marketbeat.comH.C. Wainwright maintains buy rating on Tenaya Therapeutics stockFebruary 4, 2025 | msn.comTenaya Therapeutics receives $8M clinical grant from CIRMFebruary 3, 2025 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Tenaya Therapeutics (NASDAQ:TNYA)HC Wainwright reaffirmed a "buy" rating and set a $18.00 price objective on shares of Tenaya Therapeutics in a research report on Monday.February 3, 2025 | marketbeat.comTenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative MedicineFebruary 3, 2025 | globenewswire.comTenaya Therapeutics announces option repricing to retain staffJanuary 29, 2025 | msn.comTD Cowen Reaffirms Their Buy Rating on Tenaya Therapeutics (TNYA)January 22, 2025 | markets.businessinsider.comAnalysts Set Tenaya Therapeutics, Inc. (NASDAQ:TNYA) PT at $17.33Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) have been given an average recommendation of "Buy" by the six brokerages that are presently covering the company, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 1 year price objectJanuary 16, 2025 | marketbeat.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Short Interest UpdateTenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) was the target of a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 12,420,000 shares, a decline of 25.6% from the December 15th total of 16,690,000 shares. Based on an average daily volume of 4,710,000 shares, the short-interest ratio is currently 2.6 days. Approximately 18.9% of the company's stock are sold short.January 15, 2025 | marketbeat.comPromising Advancements in Tenaya Therapeutics’ Cardiac Gene Therapy Justify Buy RatingJanuary 15, 2025 | markets.businessinsider.comTenaya Therapeutics: Promising Clinical Pipeline and Strategic Milestones Justify Buy RatingJanuary 15, 2025 | markets.businessinsider.comTenaya Therapeutics (NASDAQ:TNYA) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and issued a $18.00 target price on shares of Tenaya Therapeutics in a report on Tuesday.January 14, 2025 | marketbeat.comTenaya Therapeutics: Promising Pipeline and Upcoming Data Releases Support Buy RatingJanuary 13, 2025 | markets.businessinsider.comTenaya Therapeutics: Promising Clinical Advancements and Strategic Focus Support Buy RatingJanuary 13, 2025 | markets.businessinsider.comTenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated MilestonesJanuary 13, 2025 | globenewswire.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Consensus Recommendation of "Buy" by BrokeragesTenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) has been given a consensus rating of "Buy" by the six brokerages that are covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have covereJanuary 13, 2025 | marketbeat.comTenaya Therapeutics: TN-201 Isn't The Only Shot On Goal Targeting Heart DiseaseDecember 30, 2024 | seekingalpha.comShort Interest in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Grows By 18.8%Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) was the recipient of a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 16,690,000 shares, an increase of 18.8% from the November 30th total of 14,050,000 shares. Currently, 25.4% of the shares of the stock are sold short. Based on an average trading volume of 4,350,000 shares, the days-to-cover ratio is currently 3.8 days.December 29, 2024 | marketbeat.comTenaya Therapeutics (NASDAQ:TNYA) Receives "Buy" Rating from Chardan CapitalChardan Capital reaffirmed a "buy" rating and issued a $18.00 target price on shares of Tenaya Therapeutics in a report on Wednesday.December 18, 2024 | marketbeat.comHC Wainwright Reiterates Buy Rating for Tenaya Therapeutics (NASDAQ:TNYA)HC Wainwright reaffirmed a "buy" rating and issued a $18.00 target price on shares of Tenaya Therapeutics in a research report on Wednesday.December 18, 2024 | marketbeat.comPromising Early Data from Tenaya Therapeutics’ TN-201 Program Justifies Buy RatingDecember 18, 2024 | markets.businessinsider.comPositive Buy Recommendation for Tenaya Therapeutics Based on Promising TN-201 Gene Therapy ResultsDecember 17, 2024 | markets.businessinsider.comTenaya Reports Early Data From First Cohort Of Patients In MyPEAK-1 Trial Of TN-201December 17, 2024 | markets.businessinsider.comTenaya in selloff after early-stage data for gene therapyDecember 17, 2024 | msn.comTenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024December 16, 2024 | globenewswire.comJacobs Levy Equity Management Inc. Purchases 226,466 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA)Jacobs Levy Equity Management Inc. boosted its position in shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) by 204.4% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 337,265 shares of the company's stock after buDecember 10, 2024 | marketbeat.comRA Capital Management L.P. Sells 639,760 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA)RA Capital Management L.P. trimmed its position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) by 8.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,982,587 shares of the company's stockDecember 5, 2024 | marketbeat.comPositive Outlook for Tenaya Therapeutics: Strong Potential in Gene Therapy for Cardiovascular Diseases Supports Buy RatingNovember 26, 2024 | markets.businessinsider.comPositive Outlook for Tenaya Therapeutics Amidst Strategic Advancements in PKP2-ARVC Gene TherapyNovember 26, 2024 | markets.businessinsider.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Consensus Rating of "Buy" from BrokeragesShares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) have earned an average rating of "Buy" from the seven brokerages that are presently covering the stock, MarketBeat reports. Seven research analysts have rated the stock with a buy recommendation. The average 1-year price objectiveNovember 24, 2024 | marketbeat.comTenaya Therapeutics Reports Q3 2024 Progress and Financial ResultsNovember 22, 2024 | markets.businessinsider.comTenaya Therapeutics reports inducement grants under Nasdaq listing ruleNovember 20, 2024 | markets.businessinsider.comTenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)November 19, 2024 | finance.yahoo.comHC Wainwright Has Bullish Forecast for TNYA FY2024 EarningsTenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - HC Wainwright lifted their FY2024 earnings per share (EPS) estimates for shares of Tenaya Therapeutics in a report issued on Thursday, November 7th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per shareNovember 11, 2024 | marketbeat.comLeerink Partnrs Has Bullish Outlook for TNYA FY2024 EarningsTenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - Equities research analysts at Leerink Partnrs increased their FY2024 EPS estimates for Tenaya Therapeutics in a research report issued on Wednesday, November 6th. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($1November 11, 2024 | marketbeat.comWhat is Lifesci Capital's Forecast for TNYA FY2024 Earnings?Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - Stock analysts at Lifesci Capital upped their FY2024 earnings estimates for shares of Tenaya Therapeutics in a research report issued to clients and investors on Wednesday, November 6th. Lifesci Capital analyst C. Jubinville now forecasts thNovember 11, 2024 | marketbeat.comEquities Analysts Set Expectations for TNYA FY2024 EarningsTenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - Equities research analysts at William Blair boosted their FY2024 EPS estimates for shares of Tenaya Therapeutics in a research note issued to investors on Wednesday, November 6th. William Blair analyst S. Corwin now forecasts that the companNovember 11, 2024 | marketbeat.comTenaya Therapeutics price target raised to $18 from $16 at CanaccordNovember 10, 2024 | markets.businessinsider.comPromising Developments and Strong Financials Drive Buy Rating for Tenaya TherapeuticsNovember 8, 2024 | markets.businessinsider.comPositive Outlook for Tenaya Therapeutics: Strong Clinical Progress and Financial Position Justify Buy RatingNovember 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Tenaya Therapeutics Amid Positive DSMB Update and Strong Financial PositionNovember 7, 2024 | markets.businessinsider.comTenaya Therapeutics (NASDAQ:TNYA) Price Target Lowered to $18.00 at Chardan CapitalChardan Capital cut their price target on Tenaya Therapeutics from $20.00 to $18.00 and set a "buy" rating for the company in a report on Thursday.November 7, 2024 | marketbeat.comTenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 6, 2024 | globenewswire.com550,700 Shares in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Bought by abrdn plcabrdn plc acquired a new position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The firm acquired 550,700 shares of the company's stock, valued at approximately $1,063,000. abrdn plc owned 0.70% of Tenaya TheNovember 5, 2024 | marketbeat.comHere's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn SituationNovember 2, 2024 | uk.finance.yahoo.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Recommendation of "Buy" by AnalystsTenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) has received an average rating of "Buy" from the seven brokerages that are presently covering the company, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating. The average 12 month target price among bOctober 30, 2024 | marketbeat.comTD Cowen Sticks to Their Buy Rating for Tenaya Therapeutics (TNYA)October 22, 2024 | markets.businessinsider.comOptimistic Outlook for Tenaya Therapeutics Amid Positive Trial Developments for TN-201October 22, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Tenaya Therapeutics (TNYA), Sana Biotechnology (SANA)October 19, 2024 | markets.businessinsider.com Get Tenaya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter. Email Address TNYA Media Mentions By Week TNYA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TNYA News Sentiment▼0.000.58▲Average Medical News Sentiment TNYA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TNYA Articles This Week▼02▲TNYA Articles Average Week Get Tenaya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Prime Medicine News Today Esperion Therapeutics News Today REGENXBIO News Today Tourmaline Bio News Today MBX Biosciences News Today Aurora Cannabis News Today Terns Pharmaceuticals News Today Foghorn Therapeutics News Today Taysha Gene Therapies News Today Cryoport News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TNYA) was last updated on 2/20/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredFeb. 26 Could Send Nvidia’s “Silent Partners” SoaringNvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenaya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TNYA Stock Alerts